Comparative effectiveness of take-home dosing schedules for opioid agonist treatment in British Columbia, Canada: a target trial emulation protocol using a population-based observational study.  Kurz M, Guerra-Alejos BC, Hossain MB, Min JE, Ya…

Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework.  Leece P, Khorasheh T, Zerger S, Corace K, Nixon L, Strike C, Bayomi AM, Marks E, Holowaty M, Crichlow…

Harnessing telemedicine to deliver patient-centered opioid agonist treatment within a community-based harm reduction service: a mixed methods evaluation.  Høj SB, Coignard-Friedman R, Sako A, de Montigny C, Beauchemin-Nadeau MÈ, Léandre R, Min…

U.S. states opting out of expanded methadone take-home policies and associated mortality.  Roy V, Buonora MJ, Murray-Krezan C, Fabio A, Joudrey PJ.  J Subst Use Addict Treat. 2025 Dec;179:209800. doi: 10.1016/j.josat.2025.209800. Epub 20…

Anteil von Personen in Substitutionsbehandlung im Kanton Zürich mit medizinischen Opioiden als Einstiegssubstanz - ein Update VON LAURENT BECCIOLINI, C ARLOS NORDT, PATRIK ROSER & M ARCUS H ERDENER RESULTATE AUS DER BEGLEITEVALUATION DER OPIOI…

Cost of implementing evidence-based practices to reduce opioid overdose fatalities in New York State communities.  Li, J.M., Gruss, D., Hunt, T. et al. Addict Sci Clin Pract 20, 77 (2025). doi.org/10.1186/s13722-025-00606-6 https:/…